← all works
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Cervical Cancer and HPV Research
- Field
- Medicine
- Canadian institutions
- University of AlbertaMcGill University
- Funders
- GlaxoSmithKline
- Keywords
- Bivalent (engine)MedicineHuman papillomavirusHuman papillomavirus vaccineRandomized controlled trialVirus-like particleVaccine efficacyVirologyVaccinationInternal medicineBiologyCervical cancerGardasilCancerRecombinant DNA
- Has abstract in OpenAlex
- no